Document is current
Any future updates will be listed below
-
Authors
Höglinger, Günter http://orcid.org/0000-0001-7587-6187
,
Bähr, Mathias
Becktepe, Jos
Berg, Daniela
Brockmann, Kathrin
Buhmann, Carsten
Ceballos-Baumann, Andrés
Claßen, Joseph
Deuschl, Cornelius
Deuschl, Günther
Dodel, Richard
Ebersbach, Georg
Eggers, Carsten
van Eimeren, Thilo
Fanciulli, Alessandra
Fimm, Bruno
Folkerts, Ann-Kristin
Gausepohl, Madeleine
Hasan, Alkomiet
Hermann, Wiebke
Hilker-Roggendorf, Rüdiger
Höglinger, Günter
Höllerhage, Matthias
Hopfner, Franziska
Jost, Wolfgang
Kalbe, Elke
Kassubek, Jan
Klebe, Stephan
Klein, Christine
Klietz, Martin
Koeglsperger, Thomas
Kühn, Andrea
Krack, Paul
Krismer, Florian
Kuhlenbäumer, Gregor
Levin, Johannes
Liepelt-Scarfone, Inga
Lingor, Paul
Loewenbrück, Kai
Löhle, Matthias
Lorenzl, Stefan
Maaß, Sylvia
Maetzler, Walter
Menzel, Regina
Meyer, Philipp T
Mollenhauer, Brit
Neumann, Manuela
Odin, Per
Outeiro, Tiago
Pötter-Nerger, Monika
Reese, René
Reetz, Kathrin
Rieß, Olaf
Ruf, Viktoria
Schneider, Anja
Schrader, Christoph
Schnitzler, Alfons
Seppi, Klaus
Sixel-Döring, Friederike
Storch, Alexander
Tönges, Lars
Trenkwalder, Claudia
Walter, Uwe
Wächter, Tobias
Warnecke, Tobias
Wegner, Florian
Winkler, Christian
Witt, Karsten
Woitalla, Dirk
Zeuner, Kirsten
Trenkwalder, Claudia
-
Funding
Funding for this research was provided by:
Universitätsklinik München
- License Information
-
More Information
Article History
Received: 18 April 2024
Accepted: 19 April 2024
First Online: 6 June 2024
Declarations
:
: Not applicable.
: Given by all authors and the Deutsche Gesellschaft für Neurologie (DGN).
: Günter Höglinger has ongoing research collaborations with Roche, UCB, Abbvie; served as a consultant for Abbvie, Alzprotect, Amylyx, Aprinoia, Asceneuron, Bayer, Bial, Biogen, Biohaven, Epidarex, Ferrer, Kyowa Kirin, Lundbeck, Novartis, Retrotope, Roche, Sanofi, Servier, Takeda, Teva, UCB; received honoraria for scientific presentations from Abbvie, Bayer, Bial, Biogen, Bristol Myers Squibb, Esteve, Kyowa Kirin, Pfizer, Roche, Teva, UCB, Zambon; received publication royalties from Academic Press, Kohlhammer, Springer and Thieme; all without relevant impact on the guidelines and this article.Claudia Trenkwalder is Section Editor for Neurological Research and Practice.
